Phase I PAnTHA Study Evaluates PSMA-Targeted Actinium-225 in mCRPC Patients - Fred Saad
Fred Saad
Fred Saad discusses PAnTHA, a phase 1 first-in-human study of actinium-225 PSMA-targeted radioligand therapy in mCRPC, using a Macropa chelator at doses from 75 to 150 kBq/kg in four six-week cycles.
